Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × HER2-Positive Early Breast Cancer × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 3202 Carcinoma, Non-Small-Cell Lung 2697 Breast Neoplasms 2528 Colorectal Neoplasms 1438 Prostatic Neoplasms 1287 Neoplasm Metastasis 1285 Multiple Myeloma 1098 Melanoma 1098 Ovarian Neoplasms 994 Lung Neoplasms 937 Recurrence 914 Leukemia, Myeloid, Acute 871 Pancreatic Neoplasms 822 Lymphoma, Non-Hodgkin 761 Lymphoma 710 Stomach Neoplasms 685 Carcinoma, Renal Cell 654 Carcinoma, Hepatocellular 641 Leukemia, Lymphocytic, Chronic, B-Cell 556 Squamous Cell Carcinoma of Head and Neck 544 Lymphoma, Follicular 508 Head and Neck Neoplasms 486 Glioblastoma 470 Lymphoma, Large B-Cell, Diffuse 439 Small Cell Lung Carcinoma 438 Triple Negative Breast Neoplasms 429 Leukemia 422 Uterine Cervical Neoplasms 419 Advanced Solid Tumors 419 Urinary Bladder Neoplasms 405

Interventions

pertuzumab 1 Trastuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03674112 2024-01-02

PHranceSCa

Hoffmann-La Roche

Phase 2 Completed

160 enrolled 53 charts

HER2-Positive Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡